PRAME and synovial sarcoma: To specifically target CTA, including NY-ESO-1, or MAGE-A4, or PRAME, adoptive transfer of antigen-specific T-cell receptor-transduced T (TCR-T)-cells has shown promise for the metastatic SS treatment in several early phase clinical trials: efficacy was reached along with manageable safety profile (the most common adverse events were cytopenias in 25–75% cases) [15,74].